Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
Kate Franklyn(Monash University), Eric F. Morand(Novartis (Switzerland)), Sandra Navarra(University of Santo Tomas), Shun Le Chen(Shanghai Jiao Tong University), Alberta Hoi(Monash Health), Worawit Louthrenoo(Chiang Mai University), Cesarius Singgih Wahono(University of Brawijaya), Laniyati Hamijoyo(Dr. Hasan Sadikin General Hospital), Susan Morton(Monash University), Aisha Lateef(National University Hospital), Ou Jin(Sun Yat-sen University), Chak Sing Lau(University of Hong Kong), Molla Huq(University of Melbourne), Mandana Nikpour(The University of Sydney)
Cited by 728
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
|Nature Medicine|2016|570
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478